Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that both the etiology and the incidence rate of retinal vasculitis after Syfovre injections remain uncertain. Put in more … [Read more...]
Syfovre Eye Injuries Decreased Vision For Patients After Syfovre Treatments
Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in … [Read more...]
Syfovre Vision Side Effects Cases Reported at Ophthalmology Meeting
A Syfovre vision side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November. William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre vision side effects cases ranging from hemorrhagic occlusive vasculitis-type … [Read more...]
Syfovre Eye Injections Adverse Reactions Update August 2023
We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS). Apellis Pharmaceuticals said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss … [Read more...]
Syfovre-related Vision Loss Reported In Patients After Their First Injection
Syfovre-related vision loss has been reported in patients after the first time they used a Syfovre injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre-related vision loss as well as some other … [Read more...]
Syfovre Retinal Vasculitis Cases Warning Letter July 2023
The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow … [Read more...]
EzriCare Artificial Tears Case Reports Involving Vision Loss
A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma. The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal … [Read more...]
EzriCare and Delsam Products Recall: March 2023 Update
Here is the most recent information from the US Centers for Disease Control and Prevention (CDC) about the EzriCare and Delsam products recall for case reports associated with bacterial contamination: As of March 1, 2023, CDC, in partnership with state and local health departments, identified 64 patients in 13 states (CA, CO, CT, FL, IL, NJ, NM, … [Read more...]
EzriCare and Delsam Pharma’s Eye Drops Products Recall
In early February 2023 there was an artificial tears lubricant eye drops products recall involving EzriCare and Delsam Pharma’s Artificial Tears. As a standard practice, when a drug company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. Here is the Global Pharma Healthcare … [Read more...]
EzriCare Artificial Tears Eye Infections Warnings
There is detailed information about the in this Centers for Disease Control and Prevention (CDC) Outbreak and Patient Notifications article, “Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears”, including this fact: As of January 31, 2023, CDC, in partnership with state and local health departments, … [Read more...]